Skip to content

Gossamer Bio, Inc.

GOSS

CIK 0001728117 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
$51.63M
−57.7% YoY Q1 May 2026
Net Income (TTM)
−$169.8M
−201.4% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.74
−200.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-328.4%
Q1 May 2026
Net Margin
-328.9%
Q1 May 2026
Free Cash Flow (TTM)
−$183.76M
Q1 May 2026
Cash
$41.03M
Q1 May 2026
Total Debt
$11.61M
Q1 May 2026
Shares Outstanding
234.7M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings